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Methods that are available for male contraception, namely coitus interruptus, condoms, and vasectomy, have been
used since the 19th century. With the exceptions of a few improvements of these methods, no major progress has been made
with respect to introducing new male contraceptives since then. It is extremely urgent to develop new, safe, effective, and
reversible male contraceptive methods. Among all male contraceptive methods that are being investigated, the hormonal
approach is the closest to clinical application. Hormonal contraception provides pregnancy protection by means of
spermatogenic suppression. Androgen-progestin regimens currently represent the best available hormonal combination for
induction of a profound suppression of spermatogenesis. Further development of new steroids is mandatory for increasing
the choices of available contraceptive formulations and to optimize long-term safety of these regimens.
DESCRIPTORS: Testosterone. Androgen. Hormones. Contraception. Sterile.
During recent decades, the most
important trends in family planning
services have been improvement in the
quality of care, reaching out to new
population groups such as men and
adolescents, and integrating family
planning services into other reproduc-
tive health services1.
A number of methods aimed at the
suppression of sperm production, the
inhibition of sperm motility, or the
prevention of sperm transport are un-
der development2,3. However, new con-
traceptive methods are still not avail-
able for the male. The reasons for this
are numerous, including insufficient
research funding, lack of interest by
both the scientific community and
pharmaceutical companies, fear of side
effects, and doubts regarding accept-
ability, as well as those inherent in the
difficulty of the task. Of these obsta-
cles, at least the doubts as to accept-
ability seem to be unfounded, since re-
cent surveys show that well over 50%
of men would use “the pill” if it were
available2,3. Of all the different contra-
ceptive strategies tested for the male,
the hormonal methods come closest to
the ideal (Table 1)4 . Considerable
progress recently has been made in this
field, in particular with the multicenter
contraceptive efficacy trials of the
World Health Organization.5,6 These
studies have established the feasibil-
ity of hormonal male contraception
and have clearly identified the prob-
lems that still remain before such a
method is ready for wider use. The
awakening of interest of the pharma-
ceutical industry in the development
of male hormonal contraceptives is an
encouraging sign, and the first “male
pill” might be available in a few years.
Nonhormonal methods
Extracts of the Chinese medicinal
plant Tripterygium wilfordii have been
shown to contain compounds that
cause infertility in male rats. One of
them, triptolide, appears to be effective
in reducing epididymal sperm concen-
tration and in inducing an almost
complete loss of sperm motility7.
These characteristics make it an attrac-
tive lead as it is a substance that would
induce infertility without suppressing
spermatogenesis, would act quickly,
and would be easily reversible8.
Further, several chemical com-
pounds including a-chlorohydrin, 6-
chloro-6-deoxy sugars, gossypol, and
triptolide have been shown to inhibit
either spermatogenesis or epididymal
sperm maturation9; however, their se-
vere side effects, such as hypokalemia,
276
REV. HOSP. CLÍN. FAC. MED. S. PAULO 58(5):275-283, 2003Trends in male contraception
Pasqualotto FF et al.
neurotoxicity, immunosuppression,
and irreversibility of azoospermia, pre-
clude them from use in humans.
The strategies of nonhormonal
male contraception relate to the phar-
macological inhibition of testicular
sperm production, in particular meio-
sis, and disruption of sperm maturation
in the epididymis.
Our knowledge of the molecular
and cell biology of spermatogenesis
and sperm maturation has increased
greatly. Findings regarding reproduc-
tive failures are often made in
transgenic and knockout mice. It is
possible that these studies will iden-
tify single genes that are critical in the
production of fertile sperm. If such a
gene codes for, for instance, a testis or
germ cell-specific enzyme, receptor, or
ion channel, specific blockage of its
function by pharmacological means
could be feasible. Such findings would
provide concepts for the development
of specific nonhormonal male contra-
ceptives. Unfortunately, despite its
clear potential, such a method must
await future development9,10.
Immunological methods
Clinical observations have sug-
gested that the presence of antisperm
antibodies might be a cause of infer-
tility and might also explain the low
pregnancy rate observed after vasec-
tomy reversal11. Since the presence of
antisperm antibodies is not associated
with any side effects other than infer-
tility, the option of developing an
antisperm vaccine seems possible.
However, to date the difficulty in this
approach has been the identification of
an appropriate antigen and the avoid-
ance of possible irreversible effects in
the testis. Other approaches based on
anti-FSH (follicle-stimulating hor-
mone), anti-FSH receptor or anti-GnRH
are being investigated as possible in-
hibitors of gametogenesis.
Improved methods for male
sterilization
Vasectomy is easy to perform and
has fewer associated complications
compared to female sterilization, but
the need for a skin incision, and the
lack of assured reversibility appear to
be the main issues limiting its accept-
ability. Two major techniques have
been developed to overcome these prob-
lems: the no-scalpel method of vasec-
tomy, which is gaining in popularity,
and the percutaneous nonsurgical vas
occlusion technique12. Occlusion tech-
niques based on polyurethane or me-
thylcyanoacrylate have been shown to
have high local toxicity, with local re-
action and occlusion on either side of
the plug. Methods using silicone are
under evaluation13. A new approach to
nonsurgical vas occlusion under study
involves an injection into the vas def-
erens of a preparation of styrene maleic
anhydride dissolved in dimethyl sul-
foxide. In monkeys, this approach has
been shown to be reversible using a
combination of palpation and percuta-
neous electrical stimulation14.
Non-latex male condoms
Advantages of non-latex condoms
over latex condoms are that they are
loose-fitting except at the base of the
penis, are stronger in vitro, do not de-
teriorate in storage, are not affected by
oil-based lubricants, and can be used
by individuals who are allergic to la-
tex. Polyurethane condoms as Avanti®
and styrene-based plastic condoms
such as Tactylon®15 are already on the
market, and others are under develop-
ment. Clinical trials with Avanti16 sug-
gest that it may have higher slippage
and breakage rates than the male latex
condom; however, its acceptability is
generally greater. The cost of these de-
vices is likely to remain an obstacle to
their widespread use in national fam-
ily planning programs.
Principles of hormonal male
contraception
The purpose of hormonal male
contraception is to alter the endocrine
environment of the body in such a way
that the hormonal control of sperma-
togenesis is blocked. Spermatogenesis
requires the stimulatory action of the
two pituitary gonadotropins, luteiniz-
ing hormone (LH) and follicle-stimu-
lating hormone (FSH). The role of LH
is to stimulate Leydig cell testosterone
production and to maintain the very
high intratesticular testosterone con-
centration (100-fold compared to pe-
ripheral circulation) that is needed for
spermatogenesis. The role of FSH is
less clear, but it seems to be important
for the maintenance of qualitatively
normal spermatogenesis by stimulat-
ing the recruitment of spermatogonia
into the spermatogenic maturation
process. Hence, the effective suppres-
sion of gonadotropins, in particular
that of the LH/testosterone link, can be
expected to inhibit spermatogenesis.
Although FSH action is also involved
in spermatogenesis, the selective inhi-
bition of FSH is not enough to inhibit
it, as has been demonstrated recently
in mice with disrupted function
Table 1 - Requirements of an ideal male contraceptive method.
As effective as comparable female methods
Acceptable to both partners
Rapidly effective
Free of side effects and especially without influence on masculinity, libido, and potency
Without influence on progeny
Reversible with regard to fertility
Easily available and financially affordable
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(knockout) of the FSH b-subunit and
FSH receptor genes17-19 and in men
with an inactivating mutation in the
FSH receptor gene20. This finding casts
doubts on the efficacy of male contra-
ceptive strategies involving the inhi-
bition of FSH action or the manipula-
tion of inhibin levels.
The elimination of testicular testo-
sterone production by gonadotropin
suppression also suppresses the extra-
gonadal levels of androgens, thereby
abolishing their anabolic effects on
potency and libido. To avoid this,
physiologically low levels of pe-
ripheral testosterone have to be main-
tained by androgen supplementation.
The physiological testosterone levels
needed are so low that they do not
reinitiate spermatogenesis – as stated
before, the normal intratesticular tes-
tosterone concentration is 100-fold
higher than that found in the periph-
eral circulation.
Gonadotropin suppression can be
achieved by a variety of hormonal regi-
mens (Table 2). An ideal alternative is
testosterone itself, since it has the ad-
vantage that the same compound pro-
duces both gonadotropin suppression
and the supplementation of peripheral
androgen levels. If the dose given
slightly exceeds the physiological
maintenance dose, gonadotropin and
testicular testosterone production are
blocked, but peripheral testosterone
levels are preserved to maintain the
physiological extragonadal action of
the androgens. The other practically
feasible antigonadotropin agents in-
clude progestins and gonadotropin re-
leasing hormone (GnRH) analogs.
Since these hormones only provide the
gonadotropin suppression, androgen
supplementation must be included in
the regimen to maintain the extrago-
nadal activity of the androgens.
Feasibility of hormonal male
contraception: the WHO
multicenter trials
Clinical trials testing the suppres-
sion spermatogenesis by androgen
treatment have been conducted since
the late 1970s. A common feature of
these trials is that about two-thirds of
the men involved, usually of Cauca-
sian origin, display reversible suppres-
sion of spermatogenesis to the point of
azoospermia, while variable suppres-
sion is observed in the rest, usually to
the point of severe oligozoospermia.
The first World Health Organization
(WHO) multicenter study showed that
the azoospermia achieved in this fash-
ion, using a standard regimen of 200
mg testosterone enanthate (TE) per
week intramuscularly, resulted in effec-
tive contraception5. The men partici-
pating developed azoospermia, used
no other form of contraception for 12
months, and among the 137 couples
involved, only 1 pregnancy occurred.
The compliance of the men was good,
the side effects were tolerable, and in
all cases the antispermatogenic effect
was reversible. An interesting feature
was that the rate of azoospermia was
much greater in men of Asian origin
than among Caucasians (91% vs. 60%).
The second phase of the WHO
study consisted of an investigation
into the extent to which the fertility of
men displaying severe oligozoosper-
mia may be affected6. Using a similar
study protocol, men with oligo-
zoospermia below 3 X 106/mL were al-
lowed to begin a 12-month use of tes-
tosterone. Altogether, of the 349 men
entering study, 77% remained consist-
ently azoospermic, 10% were consist-
ently oligozoospermic but never
azoospermic, and 13% fluctuated be-
tween oligozoospermia and azoosper-
mia. Only 2.2% failed to achieve the
required azoospermia or oligozoosper-
mia (< 3.0 X 106/mL). No pregnancies
occurred amongst the azoospermic
men, but in those with oligozoosper-
mia, pregnancies occurred at a rate of
8.1 per 100 persons/year. The likeli-
hood of contraceptive failure was di-
rectly related to the remaining sperm
count.
The combined efficacy rate of the
200 mg/week testosterone enanthate
(TE) method is similar to those of hor-
monal female methods but superior to
the reversible male methods (con-
doms, withdrawal, periodic absti-
nence). The risk of pregnancy is al-
most exclusively in the oligozoos-
permic group. Whether this rate of
contraceptive efficacy is enough or
whether only 100% azoospermic can
be accepted is a matter of debate. It
may be feasible to state that, on the
basis of these findings, azoospermia
should be set as a goal for future de-
velopmental work on this method.
It is evident that weekly testoster-
one injections, as used in the WHO tri-
als, are not practical means of male
contraception and have served prima-
rily to prove that the principle works.
Once a method with satisfactory con-
traceptive efficacy has been devel-
oped, the challenge of developing a
more practical means of administration
Table 2 - The various strategies for
hormonal male contraception.
1. Testosterone alone
testosterone enanthate in oil
testosterone pellets
testosterone microspheres
2. New parenteral testosterone preparations
testosterone buciclate
testosterone undecanoate
3. Testosterone or progestins
4. Testosterone and antiandrogens
5. Testosterone and estrogens
6. Testosterone and GnRH analogs
7. Other androgens
19-nortestosterone
7α-methyl-19-nortestosterone (MENT)
5α-dihydrotestosterone
8. Immunizations
against FSH or FSH receptor
against GnRH or GnRH receptor
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of the hormone treatment can be trans-
ferred to pharmaceutical companies.
The strategies of hormonal male
contraception
Testosterone alone
In most of the earlier male hormo-
nal contraceptive trials, including those
of the WHO5,6, the androgen prepara-
tion used has been TE by intramuscu-
lar administration. In many respects,
this regimen is suboptimal in terms of
pharmacokinetics for contraceptive
purposes. The plasma androgen levels
achieved immediately after the injec-
tion are too high and display consider-
able variation at different times in rela-
tion to the injection. This may be the
reason for the side effects reported. A
weekly 200 mg TE dose has been found
optimal for contraception, but for the
above reasons it is considered unsatis-
factory for wider use.
A more prolonged and steady effect
can be achieved with testosterone im-
plants that last for 4 to 6 months21,22 and
biodegradable spheres lasting for 2-3
months23. An optimal preparation is con-
sidered to be an injectable depot that
would provide constant release of the
steroid for several months. A very prom-
ising compound in this respect is testo-
sterone buciclate (TB), synthesized un-
der the auspices of the WHO. It has a
long effective phase of 3-4 months after
a single injection. A dose of 1200 mg of
the compound in a contraceptive trial on
spermatogenic suppression was shown
to be comparable to a weekly injection
of TE24. Another promising preparation
is injectable testosterone undecanoate,
which has been given every 6 weeks in
recent successful contraceptive trials25,26,
and it is possible that even a less fre-
quent interval of treatment would be at-
tainable with this compound.
One problem with testosterone is
the relatively weak androgenic po-
tency of this molecule. Since the
amount administered has to be at least
equal to the daily production rate of
testosterone, i.e. 3-10 mg, the limited
solubility of testosterone esters in the
oil vehicles used for intramuscular in-
jection calls for large injection vol-
umes. Therefore, more potent andro-
genic molecules would be desirable.
Since the severity of the side effects of
a drug is often related to its molar
dose, more potent androgens might
also mean reduced side effects. Even
more potent androgens exist, and in
the future they might be able to re-
place the compounds currently under-
going testing.
Testosterone in combination with
some other gonadotropin-
suppressing agent
Testosterone plus progestin
The advantage of testosterone is
that the same molecules provide both
suppression of gonadotropins and sup-
plementation of peripheral androgen
levels. However, several potential ad-
vantages, including faster suppression
of spermatogenesis, increased efficacy,
reduction of the androgen load, and
potential by fewer side effects, can be
seen if the testosterone is used in com-
bination with some other agent inhib-
iting gonadotropin secretion. These
potential advantages still await prac-
tical demonstration.
Recent studies have shown that a
combination of a suboptimal dose of
testosterone, either 100 mg TE/week
intramuscularly plus levonorgestrel
500 mg/day orally27, or 4 testosterone
pellets (800 mg, 6 mg/day) plus 300
mg depot medroxyprogesterone ac-
etate28, were more effective than testo-
sterone alone in suppressing sperma-
togenesis. However, the overall effect
was comparable to that of the WHO
studies with the TE dose (200 mg/
week) that was optimal for contracep-
tive efficacy, and it remains open as to
whether improved contraceptive effi-
cacy can be achieved with the andro-
gen/progestin combination. This pos-
sibility is likely in the light of the lat-
est studies using a combination of tes-
tosterone and a variety of progestins
(dimedroxyprogesterone 75 acetate,
desogestrel, and levonorgestrel)29.
It also remains to be seen whether
the potential advantage of reducing
the androgen load and its side effects
will in fact materialize. Although
progestins effectively suppress gona-
dotropin secretion, we do not know
whether the hormone combination
works in an additive or synergistic
fashion. The latter mechanism could
be the key to achieving uniform
azoospermia in all men treated, as well
as to reducing the steroid load.
Progestins also have direct inhibitory
effects on Leydig cell steroidogenesis30
and 5a-reductase activity31, which may
further increase the antispermatogenic
effect. On the negative side, progestins
may have untoward effects on high-
density lipoprotein (HDL) choles-
terol27, and the worst possible scenario
would be that gains in increased effi-
cacy were achieved at the expense of
increased side effects. To minimize the
side effects, the androgen compo-
nent of the treatment should mimic the
endogenous plasma androgen levels as
closely as possible, while the addi-
tional antigonadotropic substance
should block gonadotropin secretion
as effectively as possible.
Testosterone plus antiandrogen
Another alternative is the use of
cyproterone acetate (CPA), which is
both an antiandrogen and antigona-
dotropic factor, due to its progesta-
tional effect. Cyproterone acetate
clearly enhances the antispermato-
genic effect of a submaximal dose of
TE (100 mg/week)32, but it remains un-
known whether the combinations of
CPA + TE offer any advantage over a
maximally effective dose of TE alone.
In theory, its main systemic effect
could be antigonadotropic in synergy
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with testosterone, and in the testes it
could additionally be antiandrogenic,
thereby eliminating the action of the
residual androgen levels.
Testosterone plus GnRH analogs
The gonadotropin releasing hor-
mone (GnRH) agonists and antagonists
are a very promising group of com-
pounds for combination with testoster-
one, especially due to their specific
suppressive effects on gonadotropins
and their very few side effects. The
GnRH agonists have paradoxical
antigonadotropic effects through the
down-regulation of the GnRH signal
transduction system. The antagonists
function as competitive inhibitors of
endogenous GnRH action.
The GnRH agonists used alone ef-
fectively suppress serum testosterone
to the castration range in prostatic can-
cer patients, which brings about effec-
tive suppression of spermatogenesis33.
Paradoxically, additional testosterone
supplementation in contraceptive tri-
als attenuates the suppressive effect of
GnRH agonists on spermatogenesis. In
12 clinical trials with various GnRH
agonists, azoospermia was achieved in
only 24 out of 106 subjects (23%). The
reason for this failure remains un-
known, but it is conceivable that the
recovery of FSH secretion during the
treatment34, together with the low re-
maining intratesticular testosterone,
could reinitiate spermatogenesis.
Therefore, the GnRH agonists have
been abandoned for further develop-
ment as male contraceptives.
The combination of testosterone
with GnRH antagonists for male con-
traception has proven much more
promising. The azoospermic effect
seems to be especially profound if the
testosterone supplementation is de-
layed and the dose is low. Since higher
doses of testosterone supplementation
reduce the contraceptive efficacy, the
marginally increased intratesticular
testosterone level, perhaps with re-
sidual gonadotropic activity, appears
critical in such failures.
The GnRH antagonists have prac-
tically no side effects other than skin
reactions with some compounds due
to the release of histamine. At present,
they do not constitute a viable alter-
native for male contraception because
of their high cost, difficulty of admin-
istration, low potency, and local irri-
tation caused.
Epididymal approaches to male
contraception
The advantage of post-testicular
contraception lies in the rapid onset of
infertility, its reversible nature, and the
rapid return to fertility once the
therapy is discontinued. Therefore,
post-testicular contraception has much
more to offer than the hormonal ap-
proaches that block testicular sperm
production and take months to reduce
spermatozoa concentration sufficiently
for effective contraception. Although
epididymal malfunction has been sug-
gested to account for 20% of all the
cases of human necrozoospermia, there
are a undoubtedly few cases of male
infertility caused by epididymal dys-
function35. Since there is increasing
evidence that human spermatozoa
within the epididymal canal undergo
a similar maturational process to that
of the sperm of other species, post-tes-
ticular contraceptives for animals
based on physiological principle of
sperm transport, maturation, and stor-
age are applicable to man.
Those approaches involving arrest
of contraction at ejaculation could be
close to clinical testing, since auto-
nomic drugs are known, have been
tested, and should shortly be available,
with only small developments in tim-
ing and modes of delivery being re-
quired36-39. Altering the composition of
epididymal fluid for contraceptive
purpose does not currently seem prom-
ising because of the lack of organ
specificity of the synthetic, secretory,
and transport process in the epidi-
dymis, although immunological se-
questration of epididymal proteins is
being seriously considered for humans.
Specific epididymal transporters need
to be better identified before drugs
that make changes in the fluid compo-
sition can be tested. Selective inhibi-
tion of sperm glycolysis is the most
successful approach in animals and
could be effective in man.
Remaining problems in the
development of a hormonal male
contraceptive
As stated above, the maximal sup-
pression of the intratesticular androgen
level is the key to hormonal suppres-
sion of spermatogenesis and is simple
in principle. A high enough dose of
testosterone, alone or in combination
with another antigonadotropic agent,
should suppress gonadotropin secre-
tion to such a low level that the Ley-
dig cell function is blocked. However,
as experience shows, there seems to be
a fine balance between success and
failure. If the antigonadotropic dose is
too low, the desired suppression of
intratesticular testosterone is not
achieved. If the androgen component
of the treatment is too high, it may
have stimulatory effects on sperma-
togenesis. Moreover, the doses of sin-
gle or multiple compounds used must
guarantee maximal efficiency with
minimal side effects. The studies so far
performed have shown convincingly
that hormonal male contraception is
possible. However, 3 main problems
remain: lack of uniform suppression to
the point of azoospermia, the mode of
hormone administration, and potential
short-term and long-term side effects.
The lack of uniform suppression to
the point of azoospermia
There is still no clear-cut answer as
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to why all men, especially those of
Caucasian origin, should not respond
to the treatment and attain azoosper-
mia. WHO scientists have assessed the
anthropometric, seminal, hormonal,
and biochemical data before, during,
and after TE treatment as potential
predictors of inconsistent azoosper-
mia40,41. The only significant findings
were that the azoospermic men had
faster rates of the decline and recov-
ery of spermatogenesis, higher pre-
treatment FSH levels, and longer-term
rebound of gonadotropins after treat-
ment. No differences were found in the
pharmacodynamics of TE as between
the 2 groups42. One study showed that
the responder had significantly lower
levels of sex-hormone-binding globu-
lin (SHBG) throughout the whole treat-
ment and lower LH and testosterone
levels at the baseline. In addition, an-
other study reports higher 5a-reductase
activity of the non-responders during
the TE therapy, which could indicate
that the suppression of bioactive an-
drogen levels may be less profound in
these men than in those achieving
azoospermia43.
No clear-cut reasons for nonuni-
form azoospermia can be identified
from the existing observations. They
give the impression that there is a sub-
tle difference in hormonal equilibrium
and set point of the feedback mecha-
nisms for gonadotropins and androgen
dependence of spermatogenesis be-
tween the 2 groups of men. It may also
be that spermatogenesis in the poor re-
sponders is less closely dependent on
androgens, or that their intratesticular
androgen production has a higher go-
nadotropin-independent component,
either autonomously or through
paracrine stimulation. It may also be
possible that some other blood-borne
factors may be able to maintain their
testicular steroidogenesis. The variable
testicular physiology may be caused
by genetic polymorphism, reflecting
borderline functional alterations in the
key gene(s) regulating spermatogen-
esis. It is even possible that the LH or
FSH receptors of these men have
polymorphisms allowing higher than
normal constitutive, non-ligand-de-
pendent signal transduction.
A genetic cause for the variable
spermatogenetic response is strongly
suggested by the ethnic differences
observed44. When Caucasian and
Asian (mostly Chinese) men were com-
pared, the rates of spermatogenic sup-
pression to the point of azoospermia
were 66.7% and 89.2%, respectively.
However, when the rates of suppression
to the point of azoospermia and/or be-
low 3 million/mL were compared, the
respective figures were 95.6% and
98.4% (thus, the ethnic difference al-
most disappeared). Hence, the differ-
ence is seen only at the lower end of
the response, from severe oligo-
zoospermia to complete azoospermia.
The mode of hormone
administration
An optimal means for hormone ad-
ministration has not yet been identi-
fied. It is clear that a long-acting de-
pot preparation would be the most de-
sirable method. Whether the active an-
drogen should be testosterone or a
synthetic androgen needs also to be
determined. The testosterone molecule
has characteristically a relatively low
rate of side effects. However, its low
intrinsic androgen activity makes it
technically difficult to use in the de-
velopment of a depot preparation,
since rather high doses of steroids are
needed. Likewise, it is still an open
question as to whether combining an-
drogen with another antigonadotropic
compound is really advantageous, be-
cause no convincing data on increased
efficiency or less intense side effects
have been presented. Nevertheless,
probably, once the problem of lack of
uniform suppression to the point of
azoospermia is solved, the develop-
ment of a suitable pharmaceutical an-
drogen preparation for wide use is a
less demanding technical challenge.
Very promising results have very re-
cently been obtained with a combina-
tion of progestin with slow-release in-
jectable testosterone esters. The opti-
mal preparation that may be within our
reach on the basis of today’s knowl-
edge could thus be a subcutaneous
progestin/androgen implant.
Potential short-term and long-term
side effects
Testosterone plays a major role in
male sexual development. Exposure of
females to testosterone in utero can in-
duce masculine characteristics such as
anovulation, increased anogenital dis-
tance, absence of nipples, retention of
male-like tissues, and agenesis of the
lower vagina. In addition, high levels
of androgens during fetal development
can lead to toxic effects such as re-
duced litter size and viability. How-
ever, there is no data regarding these
possible side effects in case of a preg-
nancy involving men taking oral con-
traceptives45.
Because healthy men will be re-
ceiving the hormonal contraceptive,
strict safety margins are required, and
the potential short-term and long-term
side effects of the therapy must be fully
recognized. Concerning acute side ef-
fects, the most common medical rea-
sons for discontinuation in the recent
treatment trials have been acne (3%)
and changes of mood, behavior, and li-
bido (4%), while other idiosyncratic or
incidental conditions were uncommon
(<1%)46. With respect to metabolic ef-
fects, a small but significant decrease
in HDL cholesterol (15-20%), but not
in other lipoproteins, is a consistent
finding47-49. The significance of these
findings remains uncertain. No sus-
tained, marked prothrombotic effects
of the treatment were found50.
From the above studies, it was con-
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cluded that the acute effects reflect the
relatively high peak levels and fluctua-
tion of plasma testosterone levels with
the weekly TE injections, rather than
an inherent feature of hormonal male
contraception, highlighting the need
for long-acting preparations of testo-
sterone with more stable delivery ki-
netics. This is suggested by the lower
frequency of the above side effects in
men treated with testosterone implants
that result in closer-to-normal physi-
ological levels of plasma testosterone
without compromising contraceptive
efficacy21.
While the role of androgens in the
progression of benign hyperplasia and
carcinoma of the prostate is well docu-
mented, it is not known whether the
lifetime exposure to androgens affects
the morbidity of these diseases. At
least theoretically, androgen therapy
increases the risk of developing
prostatic diseases. One study reported
a slight, though significant, increase
in prostatic size but no effect on pros-
tate-specific antigen (PSA)51.
One concern has been the effect of
androgens on behavior. In normal men,
supraphysiological doses of testoster-
one may result in some degree of
sexual arousal without stimulating
sexual activity, but no increase in ag-
gression has been scientifically docu-
mented52,53. Serious physiological side
effects of androgens are extremely rare,
despite reports of such cases amongst
anabolic steroid abusers. In these
cases, anabolic steroid abuse is more
likely to be the consequence than the
cause of the mental instability re-
ported54. Due to the inevitable uncer-
tainty of long-term adverse effects of
this treatment, a good approach is to
use treatments that mimic as closely as
possible the physiological androgen
production profile.
FUTURE PERSPECTIVES
In the short term, as outlined above,
3 main questions remain to be an-
swered in the development of a male
hormonal contraceptive. Once these
questions have been solved, the first
generation of hormonal male contra-
ceptives could be ready for use. It is
still difficult to predict how long it will
take to find answers to these questions.
This depends very much on the avail-
ability of research facilities, which de-
pend on the interest of the lay public,
health professionals, sociopolitical
opinion leaders, and the pharmaceuti-
cal industry. If adequate resources for
this work were to be made available
soon, the task might be completed
within the next 5 years.
RESUMO
PASQUALOTTO FF e col. - Tendênci-
as na contracepção masculina. Rev.
Hosp. Clín. Fac. Med. S. Paulo
58(5):275-283, 2003.
Métodos disponíveis para contra-
cepção como coito interrompido, pre-
servativo e vasectomia são usados des-
de o século 19. Com exceção a alguma
melhora nestes métodos, nenhum pro-
gresso maior tem sido feito com relação
à introdução de novos contraceptivos
masculinos desde então. É de extrema
urgência o desenvolvimento de um
novo método contraceptivo seguro, efe-
tivo e reversível. Entre todos os méto-
dos contraceptivos que estão sendo in-
vestigados, a abordagem hormonal é a
que está mais perto para aplicação clí-
nica. A contracepção hormonal forne-
ce proteção contra a gravidez por meio
da supressão na espermatogênese. Tra-
tamentos que incluem andrógeno e
progestágenos representam na atualida-
de a melhor combinação hormonal dis-
ponível para induzir uma profunda su-
pressão na espermatogênese. O desen-
volvimento futuro de uma nova formu-
lação esteróide é mandatório para me-
lhorar as chances de formulações
contraceptivas disponíveis e otimizar o
efeito a longo-prazo de tais regimes.
DESCRITORES: Testosterona.
Andrógeno. Hormônios. Contra-
cepção. Estéril.
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